MCID: BNG032
MIFTS: 46

Benign Mesothelioma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Benign Mesothelioma

MalaCards integrated aliases for Benign Mesothelioma:

Name: Benign Mesothelioma 12 15
Mesothelioma 43 17 71
Benign Tumor of Mesothelium 12
Adenomatoid Tumor 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2645
MeSH 43 D008654
NCIt 49 C3234
ICD10 32 C45
UMLS 71 C0025500 C0206675 C1290375

Summaries for Benign Mesothelioma

Disease Ontology : 12 A cell type benign neoplasm that has material basis in mesothelium.

MalaCards based summary : Benign Mesothelioma, also known as mesothelioma, is related to pericardial mesothelioma and malignant pleural mesothelioma, and has symptoms including snoring and coughing. An important gene associated with Benign Mesothelioma is CALB2 (Calbindin 2), and among its related pathways/superpathways is Cell surface interactions at the vascular wall. The drugs Pemetrexed and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testis.

Related Diseases for Benign Mesothelioma

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Benign Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 950)
# Related Disease Score Top Affiliating Genes
1 pericardial mesothelioma 34.4 KRT5 CALB2
2 malignant pleural mesothelioma 34.4 WT1 THBD CALB2
3 benign fibrous mesothelioma 34.2 CD34 CALB2
4 peritoneal mesothelioma 33.8 WT1 THBD CEACAM5 CALB2
5 sarcomatoid mesothelioma 33.5 WT1 THBD KRT5 CALB2
6 mesothelioma, malignant 33.4 WT1 THBD KRT7 KRT5 CEACAM5 CALB2
7 malignant epithelial mesothelioma 33.1 THBD PTGER4 CEACAM5 CALB2
8 lymphohistiocytoid mesothelioma 33.1 THBD PTGER4 CEACAM5 CALB2
9 malignant biphasic mesothelioma 33.0 WT1 THBD KRT7 KRT5 CALB2
10 asbestosis 32.6 WT1 THBD CALB2
11 spindle cell carcinoma 30.6 KRT7 KRT5 CD34
12 pleural cancer 30.6 WT1 KRT5 CEACAM5 CALB2
13 lung sarcoma 30.5 CD34 CALB2
14 sarcoma, synovial 30.4 WT1 KRT7 CD34 CALB2
15 intestinal obstruction 30.3 KRT7 CEACAM5 CD34
16 wilms tumor 5 30.2 WT1 PAX8
17 appendix adenocarcinoma 30.2 KRT7 CEACAM5
18 angiomyoma 30.2 PECAM1 CD34
19 large cell carcinoma 30.1 KRT7 KRT5 CEACAM5
20 angiosarcoma 30.1 PECAM1 KRT7 CD34 CALB2
21 peritoneal serous papillary adenocarcinoma 30.1 WT1 PTGER4
22 secretory meningioma 30.1 TRAF7 KRT7 CEACAM5
23 monophasic synovial sarcoma 30.1 KRT7 CD34 CALB2
24 fibroma 30.1 PECAM1 KRT7 CD34 CALB2
25 heart sarcoma 30.1 PECAM1 CD34
26 malignant peripheral nerve sheath tumor 30.0 WT1 KRT7 CD34
27 ovarian serous carcinoma 29.9 WT1 PAX8 CALB2
28 papillary carcinoma 29.9 PAX8 KRT7 CALB2
29 lymphangitis 29.9 PECAM1 CEACAM5
30 histiocytoid hemangioma 29.8 PECAM1 CD34
31 hemangioma 29.8 PECAM1 KRT7 CD34
32 fibrous meningioma 29.7 TRAF7 CD34
33 cystic lymphangioma 29.7 PECAM1 CD34 CALB2 AFP
34 epithelioid sarcoma 29.7 PECAM1 KRT7 CD34 CALB2
35 serous cystadenocarcinoma 29.7 WT1 PAX8 KRT7
36 lymphangioma 29.6 PECAM1 CEACAM5 CD34
37 connective tissue benign neoplasm 29.6 PECAM1 CD34 CALB2
38 lung cancer susceptibility 3 29.6 THBD PECAM1 KRT7 KRT5 CEACAM5 CALB2
39 hydrocele 29.6 PECAM1 CALB2 AFP
40 vascular cancer 29.6 PECAM1 KRT7 CD34
41 polycystic liver disease 1 with or without kidney cysts 29.5 KRT7 CEACAM5 CALB2
42 ovarian brenner tumor 29.5 WT1 THBD KRT7
43 cystadenocarcinoma 29.5 PAX8 KRT7 CEACAM5
44 suppression of tumorigenicity 12 29.5 PECAM1 KRT7 KRT5
45 cholangiocarcinoma 29.4 KRT7 CEACAM5 AFP
46 ovarian cystadenocarcinoma 29.4 PAX8 CEACAM5 CALB2
47 pericardium cancer 29.3 WT1 PTGER4 KRT7 KRT5 CEACAM5 CALB2
48 mucinous cystadenocarcinoma 29.3 KRT7 CEACAM5
49 endosalpingiosis 29.3 WT1 PAX8 KRT7 CALB2
50 renal cell carcinoma, nonpapillary 29.2 WT1 PECAM1 PAX8 KRT7 CALB2

Graphical network of the top 20 diseases related to Benign Mesothelioma:



Diseases related to Benign Mesothelioma

Symptoms & Phenotypes for Benign Mesothelioma

UMLS symptoms related to Benign Mesothelioma:


snoring, coughing

Drugs & Therapeutics for Benign Mesothelioma

Drugs for Benign Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 4 137281-23-3, 150399-23-8 60843 446556
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5 Deoxyglucose Phase 4
6 Vitamin B Complex Phase 4
7 Folic Acid Antagonists Phase 4
8 Folate Phase 4
9 Vitamin B9 Phase 4
10
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
11
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
12
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
13
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
18
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
19
Durvalumab Approved, Investigational Phase 3 1428935-60-7
20
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
21
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
22
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
23 Ranpirnase Investigational Phase 3 196488-72-9
24
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Analgesics Phase 3
27 Vitamins Phase 2, Phase 3
28 Vitamin B 12 Phase 2, Phase 3
29 Vitamin B12 Phase 2, Phase 3
30 Antiemetics Phase 3
31 Cola Phase 3
32 Liver Extracts Phase 3
33 Anesthetics Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Narcotics Phase 3
37 Analgesics, Opioid Phase 3
38 Angiogenesis Inhibitors Phase 3
39 Interferon-alpha Phase 3
40 Tin Fluorides Phase 3
41 Interferon alpha-2 Phase 3
42 Vinca Alkaloids Phase 3
43
Vinblastine Approved Phase 2 865-21-4 241903 13342
44
Megestrol acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 595-33-5 11683
45
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
46
Ibuprofen Approved Phase 2 15687-27-1 3672
47
Selenious acid Approved, Investigational Phase 1, Phase 2 7783-00-8
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
50
Trioxsalen Approved Phase 2 3902-71-4 5585

Interventional clinical trials:

(show top 50) (show all 494)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
2 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
4 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655834 Phase 4 Pemetrexed
5 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655821 Phase 4 Pemetrexed
6 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
7 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
8 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
9 Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma Completed NCT00821860 Phase 3
10 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
11 A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma Completed NCT00006231 Phase 3
12 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
13 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
14 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 vorinostat;Placebo
15 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
16 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
17 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
18 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
19 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
21 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
22 A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
23 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
24 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
25 A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
26 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Active, not recruiting NCT03063450 Phase 3 Nivolumab
27 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
28 DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial Not yet recruiting NCT04334759 Phase 3 Durvalumab;Standard Chemotherapy
29 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Not yet recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
30 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
31 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
32 A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies Withdrawn NCT02511600 Phase 3
33 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
34 Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy Unknown status NCT00794859 Phase 2 Sorafenib
35 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
36 Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
37 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
38 A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
39 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
40 A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma Unknown status NCT00685204 Phase 2 Milataxel
41 A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 Unknown status NCT01655888 Phase 2 Tremelimumab
42 Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
43 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
44 Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial) Unknown status NCT01281800 Phase 2
45 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
46 Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
47 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
48 A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma Unknown status NCT02303899 Phase 2 Gemcitabine;Imatinib mesylate
49 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
50 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine

Search NIH Clinical Center for Benign Mesothelioma

Cochrane evidence based reviews: mesothelioma

Genetic Tests for Benign Mesothelioma

Anatomical Context for Benign Mesothelioma

MalaCards organs/tissues related to Benign Mesothelioma:

40
Lung, T Cells, Testis, Testes, Lymph Node, Breast, Liver

Publications for Benign Mesothelioma

Articles related to Benign Mesothelioma:

(show top 50) (show all 15021)
# Title Authors PMID Year
1
Mediastinal malignant mesothelioma discovered in a patient with dysphagia. 61
32528683 2020
2
Differences in cancer survival by remoteness of residence: an analysis of data from a population-based cancer registry. 61
32356140 2020
3
Imaging appearance of cystic and solid mesothelioma of the tunica vaginalis. 61
32346459 2020
4
Primary Peritoneal Low-grade Serous Carcinoma in a Patient With Lynch Syndrome: A Case Report. 61
31274699 2020
5
Clinically important associations of pleurodesis success in malignant pleural effusion: Analysis of the TIME1 data set. 61
31846131 2020
6
Non-incisional pleurectomy/decortication. 61
32011679 2020
7
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy. 61
32312091 2020
8
Authors' response to "malignant mesothelioma following exposure to cosmetic talc: Association, not causation". 61
32297681 2020
9
Malignant pericardial mesothelioma: diagnostic clues in multimodality imaging. 61
32253564 2020
10
Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma. 61
32057688 2020
11
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma. 61
31634442 2020
12
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. 61
32249197 2020
13
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. 61
32448904 2020
14
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful? 61
32002813 2020
15
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful? 61
31512057 2020
16
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. 61
32236606 2020
17
Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series. 61
31832913 2020
18
Malignant mesothelioma following exposure to cosmetic talc: Association, not causation. 61
32297667 2020
19
Measurement of asbestos emissions associated with demolition of abandoned residential dwellings. 61
32208261 2020
20
Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis. 61
32524317 2020
21
Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes. 61
32574520 2020
22
Impact of Hospital Volume on Outcomes of Elective Pneumonectomy in the United States. 61
32553767 2020
23
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. 61
32540465 2020
24
Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy. 61
32549354 2020
25
Estimating the costs of genomic sequencing in cancer control. 61
32493298 2020
26
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. 61
32179179 2020
27
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. 61
32083805 2020
28
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. 61
32364316 2020
29
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients. 61
31858592 2020
30
Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. 61
32339978 2020
31
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis. 61
32339986 2020
32
Commentary: Know your enemy-Understanding futility in the battle against malignant pleural mesothelioma. 61
32122574 2020
33
Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin. 61
32382354 2020
34
Asbestos-related diseases. 61
32553000 2020
35
Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats. 61
32248600 2020
36
Secondary renal amyloidosis associated with asbestos-related pleuropulmonary diseases. 61
32535843 2020
37
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. 61
32081346 2020
38
SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma. 61
32496433 2020
39
A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT. 61
32558713 2020
40
Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy. 61
32402303 2020
41
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. 61
32516245 2020
42
Malignant asbestos-related disease in a population exposed to asbestos. 61
32515059 2020
43
HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells. 61
32284171 2020
44
Malignant mesothelioma following repeated exposures to cosmetic talc: A case series of 75 patients. 61
32175619 2020
45
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. 61
32271879 2020
46
Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review. 61
32560575 2020
47
Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. 61
32545767 2020
48
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. 61
32532926 2020
49
Is the Deciduoid Variant of Pleural Mesothelioma Significant? 61
32471571 2020
50
Commentary: Surgeon versus mesothelioma in a thoracic cage match. 61
32113722 2020

Variations for Benign Mesothelioma

Expression for Benign Mesothelioma

Search GEO for disease gene expression data for Benign Mesothelioma.

Pathways for Benign Mesothelioma

Pathways related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 THBD PECAM1 CEACAM5

GO Terms for Benign Mesothelioma

Biological processes related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of blood coagulation GO:0030195 9.37 THBD CD34
2 cellular response to gonadotropin stimulus GO:0071371 9.32 WT1 PAX8
3 metanephric S-shaped body morphogenesis GO:0072284 9.26 WT1 PAX8
4 leukocyte migration GO:0050900 9.26 THBD PECAM1 CEACAM5 CD34
5 metanephric epithelium development GO:0072207 9.16 WT1 PAX8
6 glomerular endothelium development GO:0072011 8.62 PECAM1 CD34

Sources for Benign Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....